Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer.
Antoni Vilaseca Cabo, MD
Antoni Vilaseca Cabo, MD, is an adjunct physician of the urology service at Hospital Clínic de Barcelona.
Articles by Antoni Vilaseca Cabo, MD
Antoni Vilaseca Cabo, MD, discusses phase 1 data presented on TAR-210 for the treatment of patients with FGFR-altered high- and intermediate-risk non-muscle invasive bladder cancer.